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Abstract
The relationship between clinical signiﬁcance of non-pigmented, rapidly growing mycobacteria (NPRGM), in vitro bioﬁlm development
and sliding motility was evaluated in this study. One hundred and sixty-eight clinical strains of NPRGM were included. Forty-one of
these were clinically signiﬁcant isolates. Bioﬁlm was formed by 123 strains. Seventy-six bioﬁlm-positive and 25 bioﬁlm-negative strains
showed sliding motility. There was a relationship between clinical signiﬁcance and bioﬁlm development (p <0.000 001), sliding motility
(p 0.0037) and species (p <0.000 001). No relationship was found between motility and bioﬁlm development. The ability to develop bio-
ﬁlm is a characteristic that can have importance in the development of infections caused by NPRGM.
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Introduction
Since the development of the bioﬁlm concept in the late
1970s, this structure has been recognized as an extremely
important pathogenic factor in medicine. Bioﬁlms have been
described in a high number of human infections, especially
those related to biomaterials [1,2].
Non-pigmented rapidly growing mycobacteria (NPRGM)
are a group of mycobacteria that have been involved in a
broad spectrum of human infections [3,4]. Among these dis-
eases, biomaterial-related infections are an important group,
ranging from extremely severe syndromes, such as prosthetic
valve endocarditis, to relatively mild ones, such as surgical
wound infections. Moreover, chronic syndromes caused by
these mycobacteria, which have been considered bioﬁlm-
related infections (for example respiratory tract infections
in patients with cystic ﬁbrosis) have also been described [1].
A recent study showed that such bioﬁlm-related infections
represent more than two-thirds of all infections caused by
these organisms [5].
There are several reports describing bioﬁlm development
by NPRGM [6,7]. However, only a few of them include clini-
cally relevant species [8–12] and none of them includes a
large number of clinical strains. From studies performed with
Mycobacterium smegmatis culture collection strains, it has
been claimed that there is a relationship between sliding
motility and bioﬁlm development [13,14]. However, there
are data suggesting that these properties are not necessarily
linked, at least in other species of slowly growing [15] or
rapidly growing mycobacteria [12], but no study has included
clinical strains of different species of NPRGM.
Recent studies performed with M. abscessus isogenic
strains have shown a relationship between glycopeptidoli-
pids and bioﬁlm development [11]. Interestingly, in this
report the strain that was able to develop bioﬁlm did not
show pathogenic potential in an in vivo model of infection
[11,16,17]. Mycobacterium abscessus is especially correlated
with respiratory tract infections [5], although it can cause a
broader group of syndromes [3]. It is possible that these
experimental results represent only a partial view of the
problem, and a broader study with a high number of strains
would give different results. We have already shown that a
M. abscessus type strain is able to form bioﬁlm, and under
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some conditions the growth of the bioﬁlm produced by this
strain is faster than that of other species [12].
Here we report a study analysing the relationship between
bioﬁlm development, sliding motility, and clinical signiﬁcance
in a group of clinical strains of NPRGM.
Materials and Methods
Mycobacterial strains
Clinical strains of NPRGM isolates from Madrid (Spain) were
included in the study. The strains were recovered from clinical
isolates of the Fundacio´n Jime´nez Dı´az hospital between 1990
and 2006 and from all public hospitals in Madrid (Fundacio´n
Jimenez Diaz, Hospital Universitario San Carlos, Clı´nica Puerta
de Hierro, Hospital La Princesa, Hospital Universitario La Paz,
Hospital Ramo´n y Cajal, Hospital 12 de Octubre, Hospital Uni-
versitario Gregorio Maran˜o´n) and the Hospital Universitario
de Getafe during 2005. The strains were identiﬁed according
to commonly recommended schemes, using both biochemical
tests [3] and PCR-RFLP analysis (PRA) of the Telenti fragment
of the hps65 gene [18]. When an unusual PRA pattern, or dis-
crepancies between phenotypical and genotypical methods,
was detected, the strains were sent to the Mycobacteria Labo-
ratory from the Centro Nacional de Microbiologia (Majada-
honda, Spain) to be identiﬁed using 16S rRNA gene sequencing.
After identiﬁcation, the strains were stored in skimmed milk at
)20C. After thawing, mycobacteria were checked for purity
before performing the experiment.
The clinical signiﬁcance of the strains was assessed by
reviewing the clinical charts of the patients. The evaluation
was performed according to the criteria of the American Tho-
racic Society for respiratory samples [19]. For non-respiratory
samples we considered a strain as clinically signiﬁcant if the
strain was isolated from biopsy or from several exudates and/
or characteristic pathology was found in the presence of asso-
ciated physical signs or symptoms, with improvement after
treatment. When the same organism was isolated from at least
two different body sites, or if blood or bone marrow cultures
were positive, cases were grouped as clinically signiﬁcant dis-
seminated NPRGM disease. Clinical data from these patients
have been previously published elsewhere [5,20].
Culture collection strains of M. fortuitum ATCC 6841T,
M.chelonaeATCC35752T,M.abscessusDSM44196T,M.peregri-
numATCC14467T,M.mucogenicumDSM44124, andM.mageri-
tenseATCC700351Twere included in the study as controls [12].
Sliding motility test
A motility assay was performed as described by Martinez
et al. [13]. A colony of each strain was inoculated in the
centre of a plate of motility medium (Middlebrook 7H9 (BD,
Franklin Lakes, NJ, USA) with 0.3% agar (BD) and without
supplements). The inoculated media were then incubated at
37C in a 5% CO2 atmosphere over 7 days, after which the
diameter of the bacterial growth was measured using a digital
caliper. We considered a motility test to be positive if the
diameter of the colony was >7 mm (the diameter of the
loop used to inoculate the plates), as deﬁned previously [12].
Bioﬁlm development test
The experimental protocol was developed using the method
previously described by us [12] with minimal modiﬁcations:
only Middlebrook 7H9 was used as culture medium. The
plates were incubated at ambient room temperature for
25 days. Medium was replaced on days 1, 4, 7, 11, 14, 18, 21
and 25. Photographs were obtained using a Leitz DM IL
inverted microscope (Leica, Solms, Germany) with an
attached Nikon Coolpix 8400 digital camera (Nikon, Tokyo,
Japan), and analysed to evaluate the surface area covered by
the bioﬁlm using Image J software (National Institute of
Health, Bethesda, MD, USA). The proportion of surface cov-
ered by bioﬁlm at each time point was used to construct a
growth curve of the bioﬁlm. Each strain was tested at least
two times in different experiments.
Strains that did not show bioﬁlm development were
re-tested using a more prolonged incubation time: photo-
graphs were taken on the same days plus days 28, 32, 35
and 39.
Twenty randomly selected clinical strains (four each of
M. abscessus, M. fortuitum, M. chelonae and M. peregrinum, and
two each of M. mucogenicum and M. mageritense) were also
analysed using confocal laser scanning microscopy (CLSM),
according to the previously described protocol [12].
Statistical analysis
Logistic regression analysis was performed to evaluate the
relationship between bioﬁlm development, sliding motility and
clinical signiﬁcance. In our study, we considered the clinical
signiﬁcance as response variable, and as predictors we consid-
ered the species, sliding motility, bioﬁlm development, and
the corresponding percentages of area covered by bioﬁlm at
days 1, 4, 7, 11, 14, 18, 21 and 25 (the data of percentage of
covered surface were grouped as one variable named per-
centage of covered surface). The sum of percentages can be
considered as indicative of the speed at which the bacteria
covered the surface of the well (i.e. the dynamics of bioﬁlm
growth). Bioﬁlm development was indicated only if the strain
was able to develop a bioﬁlm during the study period.
We evaluated the null hypothesis of a null effect of each
variable over the response (the clinical signiﬁcance) given by
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the other variables. In order to study this, different models
have been ﬁtted: ﬁrst, a model (hereafter referred to as the
global model) including all the predictors, and corresponding
simpliﬁed models removing: (i) the species, (ii) the sliding
motility, (iii) the bioﬁlm development and, ﬁnally, (iv) the
percentage of covered surface. The global model with all
predictors was compared with the simpliﬁed model where a
variable (or a set of variables in the case of the percentages)
is removed. The same analysis has been applied for certain
species with a high number of strains (M. chelonae and
M. fortuitum).
The relationship between colony phenotype, motility and
bioﬁlm development was investigated using chi-square and
Fisher’s exact tests.
Results
One hundred and sixty-seven clinical strains (nine M. abscessus,
two M. alvei, 30 M. chelonae, 90 M. fortuitum, ﬁve M. mageri-
tense, eight M. mucogenicum, 21 M. peregrinum, one M. porcinum
and one M. septicum) were included in the study. Forty-one of
them were clinically signiﬁcant (eight M. abscessus, 15 M. chelo-
nae, 17 M. fortuitum and one M. peregrinum). Clinical data for
these strains are shown in the Table 1.
Bioﬁlm was formed by 122 strains (73.2%). Forty-ﬁve
strains (26.8%) were unable to develop bioﬁlm. These were:
one M. abscessus (11.1% from this species), nine M. chelonae
(30%), 22 M. fortuitum (24.4%), two M. mucogenicum (25%),
ten M. peregrinum (47.6%) and the M. septicum strain (Fig. 1).
Among species with ﬁve or more strains, all M. mageritense
strains produced bioﬁlm, although none of them was consid-
ered clinically signiﬁcant. Among all other strains, percent-
ages forming bioﬁlm ranged between 52.4% (M. peregrinum)
and 88.9% (M. abscessus) (Fig. 1). All M. alvei and M. porcinum
strains were also positive for bioﬁlm development.
Considering only the clinically signiﬁcant strains, bioﬁlm
development was detected in 87.5% of M. abscessus strains,
73.3% of M. chelonae strains, 61.1% of M. fortuitum strains
and the clinically signiﬁcant strain of M. peregrinum.
Bioﬁlm-producing strains showed a sigmoid growth curve,
as previously described for collection strains (Fig. 2) (13).
No species differences in growth curves were detected.
CLSM analysis showed the presence of channels inside the
bioﬁlm when it was fully developed, together with a variable
amount of dead cells, higher at the end of the experiment.
Seventy-six of the bioﬁlm-positive (61.8%) and 25 of the
bioﬁlm-negative strains (55.6%) showed sliding motility. No
relationship between sliding motility and bioﬁlm development
was found (p 0.15).
In our study, we aimed to predict the clinical signiﬁcance
of the strains from the following variables: species, sliding
motility, bioﬁlm development and the values of the corre-
sponding percentages of covered surface, measured at days
1, 4, 7, 11, 14, 18, 21 and 25. We ﬁtted the model both with
all the variables and with each variable removed individually.
The p-values observed when we removed the following vari-
ables were: percentage covered surface 0.0232: bioﬁlm,
<0.000001: sliding motility 0.0037 and species <0.000001.
Thus, the relationship between clinical signiﬁcance and all
these variables gave signiﬁcant results. Next, a stepwise vari-
able selection was applied to the global model using all the
covered surface data. The ﬁnal model gave as predictors of
clinical signiﬁcance the percentages of covered surface at
days 1 and 21 (no statistically signiﬁcant differences were
TABLE 1. Syndromes due to clinically signiﬁcant non-
pigmented, rapidly growing mycobacteria
No Strain Species Syndrome
Bioﬁlm
production
1 FJD-4 Mycobacterium
chelonae
Skin and soft-tissue infection Positive
2 FJD-5 M. chelonae Osteomyelitis Negative
3 FJD-10 M. peregrinum Urinary tract infection Positive
4 FJD-24 M. fortuitum Skin and soft-tissue infection Negative
5 FJD-25 M. chelonae Catheter-related bacteraemia Positive
6 FJD-29 M. chelonae Catheter-related bacteraemia Positive
7 FJD-43 M. chelonae Endophthalmitis Positive
8 FJD-51 M. chelonae Skin and soft-tissue infection Negative
9 FJD-63 M. chelonae Skin and soft-tissue infection Positive
10 FJD-64 M. abscessus Skin and soft-tissue infection Positive
11 FJD-69 M. fortuitum Skin and soft-tissue infection Positive
12 FJD-84 M. chelonae Arthritis Positive
13 FJD-85 M. fortuitum Skin and soft-tissue infection Positive
14 FJD-92 M. fortuitum Skin and soft-tissue infection Positive
15 FJD-95 M. abscessus Skin and soft-tissue infection Positive
16 FJD-172 M. chelonae Bacteraemia Negative
17 FJD-176 M. chelonae Catheter-related bacteraemia Positive
18 FJD-193 M. abscessus Osteomyelitis Positive
19 FJD-207 M. fortuitum Skin and soft-tissue infection Positive
20 FJD-211 M. chelonae Skin and soft-tissue infection Positive
21 FJD-230 M. fortuitum Mammary prosthesis infection Positive
22 FJD-233 M. fortuitum Hip prosthesis infection Positive
23 FJD-241 M. fortuitum Skin and soft-tissue infection Positive
24 FJD-260 M. fortuitum Skin and soft-tissue infection Positive
25 MCM-1 M. abscessus Respiratory tract infection Positive
26 MCM-7 M. fortuitum Respiratory tract infection Positive
27 MCM-8 M. fortuitum Neck abscess Negative
28 MCM-13 M. fortuitum Canaliculitis Negative
29 MCM-14 M. chelonae Catheter-related bacteraemia Positive
30 MCM-15 M. fortuitum Surgical site infection Positive
31 MCM-16 M. chelonae Endophthalmitis Positive
32 MCM-24 M. abscessus Respiratory tract infection
(Cystic ﬁbrosis)
Positive
33 MCM-25 M. abscessus Respiratory tract infection
(Cystic ﬁbrosis)
Positive
34 MCM-28 M. fortuitum Bacteraemia Positive
35 MCM-32 M. chelonae Skin and soft-tissue infection Positive
36 MCM-53 M. fortuitum Catheter-related bacteraemia Negative
37 MCM-65 M. fortuitum Catheter-related bacteraemia Negative
38 MCM-66 M. fortuitum Catheter-related bacteraemia Negative
39 MCM-80 M. chelonae Respiratory tract infection
(Cystic ﬁbrosis)
Negative
40 MCM-83 M. abscessus Respiratory tract infection
(Cystic ﬁbrosis)
Negative
41 MCM-86 M. abscessus Respiratory tract infection
(Cystic ﬁbrosis)
Positive
CMI Martı´n-de-Hijas et al. Bioﬁlms and rapidly growing mycobacteria 933
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 931–936
detected for all other days), bioﬁlm development ability, slid-
ing motility and the different species.
Additionally, for M. chelonae and M. fortuitum (the higher
number of isolates), a stepwise variable selection was also
applied. The ﬁnal model showed the following results for the
different variables as predictors of clinical signiﬁcance: per-
centages of covered surface (p 0.0084 for M. chelonae, and p
0.066 for M. fortuitum), bioﬁlm development ability (p 0.056
for M. chelonae and p 0.018 for M. fortuitum) and sliding
motility (p 0.217 for M. chelonae and p 0.01 for M. fortuitum).
Discussion
Despite their classical image of ‘non-pathogenic’ or ‘coloni-
zing bacteria’, non-tuberculous mycobacteria have been
M. abscessus
0%
20%
40%
60%
80%
100%
M. chelonae
BIOFILM + BIOFILM –
M. forutitum M. mageritense M. mucogenicum M. peregrinum
FIG. 1. Percentages of bioﬁlm-developing strains among species with
ﬁve or more isolates. Bioﬁlm +, bioﬁlm-producing strains; Bioﬁlm ),
bioﬁlm-negative strains.
FIG. 2. Growth curves for bioﬁlm-producing strains of species with ﬁve or more isolates (data represent the mean values from all isolates of a
species). %, percentage of covered surface.
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recognized in recent years as emerging pathogens, mainly
due to the increasing number of patients susceptible to these
organisms, but also to the recognition of their importance as
human pathogens. Among these organisms, NPRGM repre-
sent a group of bacteria with different characteristics, which
make their spectrum of diseases broader than other myco-
bacteria [3,4]. Their true incidence is unknown, but is proba-
bly underestimated because of their potential identiﬁcation
as ‘diphtheroids’ [21] or simply because they are not
included in the group of organisms that are looked for in
many samples. Recently, we unexpectedly recovered
NPRGM from retrieved orthopaedic prosthesis, even though
the number of studied patients was low [5].
Almost all the cases of human infection caused by these
organisms are due to three species: M. abscessus, M. chelonae
and M. fortuitum [3,4]. One recent epidemiological study has
conﬁrmed this ﬁnding, although many other species were
isolated [5]. In the present study, species was statistically
conﬁrmed as a predictor for infection.
Infections caused by these organisms were detected in
bioﬁlm-related syndromes, such as foreign-body infections or
chronic respiratory tract infections. These data suggest that
there could be a role for bioﬁlm development as a patho-
genic factor among NPRGM.
Several studies have analysed bioﬁlm development among
these species. Most studies analysed several aspects using
M. smegmatis (an infrequent cause of human infections) col-
lection strains [22–25], only a few of them included clinically
relevant species [8–12], and none of them included a high
number of clinical strains.
To the best of our knowledge, this is the ﬁrst report anal-
ysing bioﬁlm development among a high number of clinical
strains that have also been evaluated for their role in human
infections. In our study, a signiﬁcant relationship between
bioﬁlm development ability and clinical infection has been
demonstrated, indicating that bioﬁlm development could be
an important pathogenic factor for NPRGM. This fact is of
great importance because bioﬁlms are a well-known form of
bacterial resistance against antibiotics [26,27], hence, the
ability to develop these structures can explain treatment fail-
ures of some of these infections when foreign bodies were
present [3,4]. Interestingly, all M. mageritense strains were
able to develop bioﬁlm (although the number of isolates is
very low), in spite of the fact that none of them causes true
human infection. Moreover, data for M. chelonae were
just short of a signiﬁcant relationship between bioﬁlm devel-
oping ability and clinical signiﬁcance (p 0.056), so we can
deduce that bioﬁlm formation is one factor that, in combina-
tion with others, may contribute to development of human
infections.
Another interesting result of our study concerns the
relation between sliding motility and bioﬁlm development.
Sliding motility has been deﬁned as ‘a kind of surface trans-
location produced by the expansive forces in a growing
culture in combination with special surface properties of
the cells resulting in reduced friction between cell and
substrate’ [13]. This property has been considered to be
related to the glycopeptidolipid content of the mycobacte-
rial cell wall and to other aspects of lipid metabolism
[13,14,28]. There are several reports of a relationship
between sliding motility and bioﬁlm development ability in
M. smegmatis [13,14] and M. abscessus [11]. However, other
reports state that this relationship is not uniform
[12,15,28]. Our study revealed bioﬁlm-producing strains
that were non-motile, as well as other strains that showed
sliding motility but were unable to form bioﬁlm in the test,
with no relationship established between them. Moreover,
in our report a statistical relationship between sliding motil-
ity and clinical signiﬁcance was detected, for all strains
including M. fortuitum. Despite the absence of a statistically
signiﬁcant relationship between bioﬁlm and sliding motility,
it is possible that a common factor could link both proper-
ties (probably related to lipid metabolism or the lipid
composition of the mycobacterial cell wall, as previous
reports have stated [13,14]) to the capacity of the strains
for causing human infection.
In conclusion, sliding motility and bioﬁlm-producing capac-
ity were not invariably linked among clinical strains of
NPRGM. Bioﬁlm development ability is a property that is not
uniformly present among clinical isolates of NPRGM. Never-
theless, it seems to be related to the capacity of the strains
to cause human disease.
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